Phase 1 evaluating MM402 single-ascending dose trial in adult healthy volunteers intended to characterize its tolerability, pharmacokinetics and pharmacodynamics for for Autism Spectrum Disorder (ASD)
Latest Information Update: 15 May 2025
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
Most Recent Events
- 08 May 2025 Status changed from planning to completed.
- 19 Aug 2024 New trial record